Dr. Dipen Maru and his team at MD Anderson Cancer Center were studying cancer patients who seemed to have beaten the disease when something alarming caught their attention: tiny clusters of cancer cells hiding in the liver, too small to show up on routine scans. These microscopic deposits, called micrometastases, appeared to be潜伏 — hiding and waiting — after treatment seemed successful. Now, their research published in the journal Cancer Cell offers new hope for identifying which patients might be at risk of their cancer returning.
Colorectal cancer is one of the most common cancers worldwide, and even after surgery and chemotherapy, it can come back. This happens because small numbers of cancer cells, called minimal residual disease (MRD), often survive even when scans show nothing. While blood tests can detect signs of these cells, they cannot show where the cells are hiding or why they survive treatment.
To understand this better, Dr. Maru's team examined 49 tumors from 19 patients with colorectal cancer that had spread to the liver or lungs. They used advanced genetic tools to study these tiny deposits at an extremely detailed level. What they discovered was striking: liver micrometastases appeared very early in a tumor's development and showed dormant, stem-like features that seemed to help them survive chemotherapy like hidden soldiers waiting in ambush.
The researchers identified six genes — now called MicroMetSig — that marked these hidden cancer cell deposits. Patients with higher levels of this signature, called MicroMetSig-high, had shorter disease-free survival and faced greater risk of their cancer returning, even after treatment.
The team also found that while immune cells surrounded these micrometastases, many of those defenders were exhausted and unable to fight effectively. The cancer cells were essentially turning off the body's natural defenses using the same pathways targeted by certain immunotherapy drugs.
"These findings provide critical insights into how colorectal cancer cells can hide after treatment and later return," Dr. Maru said. He noted that this tissue-based marker could one day work alongside blood tests to identify patients at higher risk of recurrence.
If validated in larger studies, this six-gene signature could help doctors know which patients need closer monitoring or additional treatment after surgery. The research also points to immune-related pathways that might be explored as new ways to target these hidden deposits before they grow into visible tumors.